A Phase 3 Study of MEDI-254 (NUMAX)
Project Description:
A Phase 3 Study of MEDI-254 (NUMAX), An Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Navajo and White Mountain Apache Infants
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals
Unserved or Under-served Populations:
Geographic Areas, Reservation
Primary Target Audience Geographic Descriptor:
State
COVID-19 Related Data:
N/A